Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study.

Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study.

Recruitment to trials is known to be difficult. Previous research suggests that a crucial factor may be participants' difficulty with the concept of randomization. This study explored patients' perceptions of randomization and reasons for consent or refusal to participate in the ProtecT st...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Mills, N, Donovan, J, Smith, M, Jacoby, A, Neal, D, Hamdy, F
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	2003

Gelijkaardige items

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
door: J. Donovan, et al.
Gepubliceerd in: (2003-01-01)

Alcohol consumption and PSA-detected prostate cancer risk--a case-control nested in the ProtecT study.
door: Zuccolo, L, et al.
Gepubliceerd in: (2013)

Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study.
door: Burton, A, et al.
Gepubliceerd in: (2013)

The ProtecT trial - Evaluating the effectiveness of treatment for clinically localised prostate cancer (ISRCTN20141297)
door: Lane, J, et al.
Gepubliceerd in: (2004)

Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.
door: Lane, J, et al.
Gepubliceerd in: (2010)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study
door: Rosario, D, et al.
Gepubliceerd in: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.
door: Rosario, D, et al.
Gepubliceerd in: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study
door: Rosario, D, et al.
Gepubliceerd in: (2012)

The protecT (prostate testing for cancer and treatment) study: Evaluating screening and treatment of clinically localised prostate cancer in the UK
door: Hamdy, F, et al.
Gepubliceerd in: (2006)

A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study).
door: Mills, N, et al.
Gepubliceerd in: (2006)

Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study.
door: Rosario, D, et al.
Gepubliceerd in: (2008)

The Prostate Testing for Cancer and Treatment (ProtecT) study: what have we learnt?
door: Hamdy, F
Gepubliceerd in: (2017)

Association of obesity with prostate cancer: A case-control study within the population-based PSA testing phase of the ProtecT study
door: Dimitropoulou, P, et al.
Gepubliceerd in: (2011)

Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study.
door: Dimitropoulou, P, et al.
Gepubliceerd in: (2011)

Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial
door: Wade, J, et al.
Gepubliceerd in: (2015)

Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study.
door: Catto, J, et al.
Gepubliceerd in: (2011)

Suitability of PSA-detected localised prostate cancers for focal therapy: Experience from the ProtecT study
door: Catto, J, et al.
Gepubliceerd in: (2011)

Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study
door: Adams, Charleen D., et al.
Gepubliceerd in: (2018)

PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysis.
door: Murad, A, et al.
Gepubliceerd in: (2009)

A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the ProtecT study).
door: Murad, A, et al.
Gepubliceerd in: (2010)

Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).
door: Murad, A, et al.
Gepubliceerd in: (2011)

Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial
door: Chris Metcalfe, et al.
Gepubliceerd in: (2020-09-01)

Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study).
door: Donovan, J, et al.
Gepubliceerd in: (2003)

The ProtecT trial: Analysis of the patient cohort, baseline risk stratification and disease progression
door: Young, GJ, et al.
Gepubliceerd in: (2020)

Mortality among nen with advanced prostate cancer excluded from the ProtecT Trial
door: Johnston, T, et al.
Gepubliceerd in: (2016)

Glycemic equipoise
door: Sanjay Kalra, et al.
Gepubliceerd in: (2017-01-01)

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial
door: S. Sanghera, et al.
Gepubliceerd in: (2020-10-01)

Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
door: Collin, S, et al.
Gepubliceerd in: (2009)

Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.
door: Lane, A, et al.
Gepubliceerd in: (2016)

A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial
door: Donovan, JL, et al.
Gepubliceerd in: (2017)

Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial.
door: Er, V, et al.
Gepubliceerd in: (2017)

Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the protecT randomised controlled trial according to treatment received
door: Neal, D, et al.
Gepubliceerd in: (2019)

Equipoise in action: A qualitative synthesis of clinicians’ practices across six randomised controlled trials
door: Halliday, A, et al.
Gepubliceerd in: (2016)

Participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise?
door: Petra C. E. Hissink Muller, et al.
Gepubliceerd in: (2018-12-01)

Prostate cancer screening and management: Caution against over-interpreting the results of the latest study, ProtecT
door: Isaac Yi Kim
Gepubliceerd in: (2023-07-01)

A partial defense of clinical equipoise
door: Scott D Gelfand
Gepubliceerd in: (2019-04-01)

Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: The ProtecT three-arm RCT
door: Hamdy, FC, et al.
Gepubliceerd in: (2020)

Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT
door: Freddie C Hamdy, et al.
Gepubliceerd in: (2020-08-01)

Equipoise and research in the current COVID-19 pandemic
door: Jill M. Pulley, et al.
Gepubliceerd in: (2021-01-01)

Conveying equipoise during recruitment for clinical trials: Qualitative synthesis of clinicians' practices across six randomised controlled trials.
door: Rooshenas, L, et al.
Gepubliceerd in: (2016)